Published in Cell Cycle on July 15, 2011
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget (2012) 1.85
Tumor hypoxia as a driving force in genetic instability. Genome Integr (2013) 0.92
Intermittent induction of HIF-1α produces lasting effects on malignant progression independent of its continued expression. PLoS One (2015) 0.80
The HIF-1α-c-Myc pathway and tumorigenesis: evading the apoptotic gate-keeper. Cell Cycle (2011) 0.77
The hallmarks of cancer. Cell (2000) 113.05
Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer (2002) 34.99
The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer (2003) 22.78
Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer (2002) 20.51
A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res (1988) 17.88
The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell (1996) 15.19
DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet (2001) 10.77
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature (1996) 10.14
Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A (1998) 9.56
Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol (1999) 9.32
Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem (2008) 7.71
Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev (2007) 7.41
Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol (2008) 7.37
The impact of O2 availability on human cancer. Nat Rev Cancer (2008) 6.84
Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev (2007) 6.35
Modelling the molecular circuitry of cancer. Nat Rev Cancer (2002) 5.43
Chromosome fragile sites. Annu Rev Genet (2007) 4.95
HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J (2004) 4.26
Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res (2004) 3.62
Biology of HIF-1alpha. Cell Death Differ (2008) 3.24
Bax and Bak independently promote cytochrome C release from mitochondria. J Biol Chem (2002) 3.18
Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res (2006) 3.05
HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol Cell (2005) 2.82
WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci U S A (2001) 2.79
Hypoxia and defective apoptosis drive genomic instability and tumorigenesis. Genes Dev (2004) 2.69
Autophagy is activated in colorectal cancer cells and contributes to the tolerance to nutrient deprivation. Cancer Res (2007) 2.39
Regulation of DNA repair in hypoxic cancer cells. Cancer Metastasis Rev (2007) 1.99
Oxygen sensing, hypoxia-inducible factor-1 and the regulation of mammalian gene expression. J Exp Biol (1998) 1.78
Hypoxia-induced genetic instability--a calculated mechanism underlying tumor progression. J Mol Med (Berl) (2006) 1.66
Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol Cancer Res (2006) 1.51
The phosphorylation status of PAS-B distinguishes HIF-1alpha from HIF-2alpha in NBS1 repression. EMBO J (2006) 1.38
HIF-1 and hypoxic response: the plot thickens. Curr Opin Genet Dev (2004) 1.34
Carrot and stick: HIF-alpha engages c-Myc in hypoxic adaptation. Cell Death Differ (2008) 1.31
The common fragile site FRA16D and its associated gene WWOX are highly conserved in the mouse at Fra8E1. Genes Chromosomes Cancer (2002) 1.22
The murine Fhit gene is highly similar to its human orthologue and maps to a common fragile site region. Cancer Res (1998) 1.19
HIF-1α confers aggressive malignant traits on human tumor cells independent of its canonical transcriptional function. Cancer Res (2011) 1.09
Leu-574 of human HIF-1alpha is a molecular determinant of prolyl hydroxylation. FASEB J (2004) 1.05
An essential role of the HIF-1alpha-c-Myc axis in malignant progression. Ann N Y Acad Sci (2009) 1.00
Genetic instability: the dark side of the hypoxic response. Cell Cycle (2005) 0.94
HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J (2004) 4.26
HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol Cell (2005) 2.82
Differential gene up-regulation by hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha in HEK293T cells. Cancer Res (2005) 2.78
Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci U S A (2006) 2.66
Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood (2008) 2.08
Time to failure after rotator cuff repair: a prospective imaging study. J Bone Joint Surg Am (2013) 1.76
Recombinant human bone morphogenetic protein-2: a randomized trial in open tibial fractures treated with reamed nail fixation. J Bone Joint Surg Am (2011) 1.58
Suppression of hypoxia-inducible factor 1alpha (HIF-1alpha) transcriptional activity by the HIF prolyl hydroxylase EGLN1. J Biol Chem (2005) 1.54
Efficacy and safety of recombinant human bone morphogenetic protein-2/calcium phosphate matrix for closed tibial diaphyseal fracture: a double-blind, randomized, controlled phase-II/III trial. J Bone Joint Surg Am (2013) 1.45
The phosphorylation status of PAS-B distinguishes HIF-1alpha from HIF-2alpha in NBS1 repression. EMBO J (2006) 1.38
Hypoxia-inducible factor-1 transactivates transforming growth factor-beta3 in trophoblast. Endocrinology (2004) 1.10
Real-time sonoelastography of hepatic thermal lesions in a swine model. Med Phys (2008) 1.10
Tumor suppressor p53 represses transcription of RECQ4 helicase. Oncogene (2005) 1.10
HIF-1α confers aggressive malignant traits on human tumor cells independent of its canonical transcriptional function. Cancer Res (2011) 1.09
Leu-574 of human HIF-1alpha is a molecular determinant of prolyl hydroxylation. FASEB J (2004) 1.05
Suppression of VEGF transcription in renal cell carcinoma cells by pyrrole-imidazole hairpin polyamides targeting the hypoxia responsive element. Acta Oncol (2006) 1.04
An essential role of the HIF-1alpha-c-Myc axis in malignant progression. Ann N Y Acad Sci (2009) 1.00
Phorbol ester stimulates the nonhypoxic induction of a novel hypoxia-inducible factor 1alpha isoform: implications for tumor promotion. Cancer Res (2003) 0.99
Nutlin-3, an Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1alpha. Carcinogenesis (2009) 0.97
Dynamic balancing of the dual nature of HIF-1alpha for cell survival. Cell Cycle (2004) 0.96
HIF-1α mediates tumor hypoxia to confer a perpetual mesenchymal phenotype for malignant progression. Sci Signal (2011) 0.95
Genetic instability: the dark side of the hypoxic response. Cell Cycle (2005) 0.94
Hypoxic suppression of the cell cycle gene CDC25A in tumor cells. Cell Cycle (2007) 0.94
Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH-mediated repression of HIF-1. Blood (2005) 0.87
From antiangiogenesis to hypoxia: current research and future directions. Cancer Manag Res (2010) 0.84
CITED2 controls the hypoxic signaling by snatching p300 from the two distinct activation domains of HIF-1α. Biochim Biophys Acta (2011) 0.81
Targeting HIF-alpha: when a magic arrow hits the bull's eye. Drug Discov Today (2004) 0.77
von Hippel-Lindau protein adjusts oxygen sensing of the FIH asparaginyl hydroxylase. Int J Biochem Cell Biol (2011) 0.75
An efficient way of studying protein-protein interactions involving HIF-α, c-Myc, and Sp1. Methods Mol Biol (2013) 0.75
Tumor acquisition for biomarker research in lung cancer. Cancer Invest (2014) 0.75
Can irradiated tumors take NO for an answer? Mol Cell (2007) 0.75